AUS
NZ
UK
CA
USA
IND
Highlights
- Mayne Pharma embroiled in legal dispute with TherapeuticsMD
- Allegations tied to a $153M women’s health portfolio deal
- Legal claims include breach of contract and unjust enrichment
Mayne Pharma (ASX:MYX) is under scrutiny following legal action initiated by TherapeuticsMD (NASDAQ:TXMD), a US-based pharmaceutical company. The dispute centers on a 2022 licensing deal where Mayne Pharma acquired a suite of women’s health products from TherapeuticsMD. That transaction, valued at approximately $153 million, was expected to enhance Mayne Pharma’s footprint in the specialty healthcare space.
However, recent court filings have turned the spotlight on unresolved financial issues tied to the deal. According to official statements from Mayne Pharma, the litigation includes claims of breach of contract and breach of the implied covenant of good faith and fair dealing. Additionally, the allegations extend to fraudulent inducement related to a prior settlement of the net working capital adjustment—a key element often used to finalize deal valuations in asset purchases.
TherapeuticsMD also claims unjust enrichment, asserting that Mayne Pharma’s financial calculations led to discrepancies in determining amounts owed under the terms of the transaction. While the specific financial impact of the legal challenge has not been disclosed, the implications could influence future licensing or acquisition strategies for both parties.
Mayne Pharma has responded by stating its intent to "vigorously defend" against all claims made in the proceedings. No additional details were provided regarding the timeline of the court case or any immediate operational impact.
The original 2022 licensing agreement was a strategic move for Mayne Pharma to deepen its presence in the U.S. women’s health market. It included products addressing contraception, hormone therapy, and prenatal care. At the time, the deal was viewed as a significant step forward for the company, aiming to build on its specialty brand portfolio in North America.
As legal proceedings develop, industry observers will be watching closely to see how this high-stakes contractual dispute unfolds. Both companies have a strong presence in the women’s health therapeutic area, and the resolution of this matter could have lasting implications for future commercial partnerships in the sector.
Investors and stakeholders in the pharmaceutical space may want to monitor updates as this case progresses through the U.S. legal system.
